Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.

Clinical pharmacology and therapeutics - 1 Jan 2003

Verstuyft Céline, Strabach Soraya, El-Morabet Hakima, Kerb Reinhold, Brinkmann Ulrich, Dubert Liliane, Jaillon Patrice, Funck-Brentano Christian, Trugnan Germain, Becquemont Laurent

Abstract excerpt

BACKGROUND: On the basis of in vitro studies indicating that dipyridamole is an inhibitor for the MDR1 efflux membrane transporter P-glycoprotein, we postulated that dipyridamole could increase the bioavailability of digoxin, a P-glycoprotein substrate. OBJECTIVES: The main objective was to determine whether dipyridamole alters the bioavailability of digoxin. The secondary objective was to determine whether the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Biological Availability
Share to Cardiotonic Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Cross-Over Studies

Share to Digoxin

Share to Genes, MDR

Share to Phosphodiesterase Inhibitors

Share to Platelet Aggregation Inhibitors

Share to Threonine

Source

Identifiers

PMID: 12545143
DOI: 10.1067/mcp.2003.8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Dipyridamole enhances digoxin bioavailability via P-glycoprotein inhibition.PMID 12545143Read ↗

Role of human MDR1 gene polymorphism in bioavailability and interaction of digoxin, a substrate of P-glycoprotein.Semantic proximity Read ↗

Modulation of steady-state kinetics of digoxin by haplotypes of the P-glycoprotein MDR1 gene.Semantic proximity Read ↗

Ritonavir decreases the nonrenal clearance of digoxin in healthy volunteers with known MDR1 genotypes.Semantic proximity Read ↗

Human intestinal P‐glycoprotein activity estimated by the model substrate digoxinSemantic proximity Read ↗

Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo.Semantic proximity Read ↗

MDR1 genotype-related pharmacokinetics of digoxin after single oral administration in healthy Japanese subjects.Semantic proximity Read ↗

Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans.Semantic proximity Read ↗

Digoxin pharmacokinetics and MDR1 genetic polymorphisms.Semantic proximity Read ↗

Modelling the influence of MDR1 polymorphism on digoxin pharmacokinetic parameters.Semantic proximity Read ↗

Meta-analysis of the influence of MDR1 C3435T polymorphism on digoxin pharmacokinetics and MDR1 gene expression.Semantic proximity Read ↗

Effect of grapefruit juice on digoxin pharmacokinetics in humans.Semantic proximity Read ↗

Frequency of single nucleotide polymorphisms in the P-glycoprotein drug transporter MDR1 gene in white subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.